Last reviewed · How we verify
Advanced breast cancer in postmenopausal women with disease progression following prior therapy — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Fulvestrant Injectable Product | fulvestrant-injectable-product | Pfizer | estrogen receptor degrader | estrogen receptor |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 1 drug in Advanced breast cancer in postmenopausal women with disease progression following prior therapy
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Advanced breast cancer in postmenopausal women with disease progression following prior therapy:
- Advanced breast cancer in postmenopausal women with disease progression following prior therapy treatment updates — RSS
- Advanced breast cancer in postmenopausal women with disease progression following prior therapy treatment updates — Atom
- Advanced breast cancer in postmenopausal women with disease progression following prior therapy treatment updates — JSON
Cite this brief
Drug Landscape (2026). Advanced breast cancer in postmenopausal women with disease progression following prior therapy — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/advanced-breast-cancer-in-postmenopausal-women-with-disease-progression-following-prior-therapy. Accessed 2026-06-10.
Related
- Advanced breast cancer in postmenopausal women with disease progression following prior therapy full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing